• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Chloroquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines Chloroquinolines

Ethyl 4-chloroquinoline-6-carboxylate (CAS No. 148018-34-2): A Versatile Intermediate in Modern Pharmaceutical Synthesis

Ethyl 4-chloroquinoline-6-carboxylate (CAS No. 148018-34-2) is a significant compound in the realm of pharmaceutical chemistry, serving as a crucial intermediate in the synthesis of various bioactive molecules. Its unique structural framework, combining a quinoline core with ester and chloro substituents, makes it a valuable building block for drug discovery and development. This article delves into the compound's chemical properties, synthetic pathways, and its emerging applications in medicinal chemistry.

The molecular structure of Ethyl 4-chloroquinoline-6-carboxylate features a quinoline ring system substituted at the 4-position with a chlorine atom and at the 6-position with a carboxylate ester group. This arrangement imparts distinct reactivity patterns, making it an attractive candidate for further functionalization. The presence of both electron-withdrawing and electron-donating groups enhances its utility in constructing complex heterocyclic scaffolds, which are prevalent in many pharmacophores.

In recent years, there has been growing interest in quinoline derivatives due to their broad spectrum of biological activities. Studies have highlighted their potential in combating infectious diseases, cancer, and neurological disorders. Among these derivatives, compounds like Ethyl 4-chloroquinoline-6-carboxylate have been explored for their ability to modulate enzyme activity and interact with biological targets. The chloro substituent at the 4-position of the quinoline ring, for instance, can participate in nucleophilic substitution reactions, allowing for the introduction of diverse functional groups.

The synthesis of Ethyl 4-chloroquinoline-6-carboxylate typically involves multi-step organic transformations starting from readily available precursors. One common approach involves the reaction of quinoline-6-carboxylic acid with thionyl chloride to form the corresponding acyl chloride, which is then esterified using ethanol under acidic conditions. Alternatively, palladium-catalyzed cross-coupling reactions can be employed to introduce the chloro group at the 4-position of the quinoline ring. These synthetic strategies highlight the compound's adaptability and ease of modification.

Recent advancements in medicinal chemistry have demonstrated the utility of Ethyl 4-chloroquinoline-6-carboxylate in designing novel therapeutic agents. For instance, researchers have utilized this intermediate to develop inhibitors targeting bacterial enzymes such as DNA gyrase and topoisomerase IV. These enzymes are critical for bacterial DNA replication and are considered key targets in antibiotic development. The quinoline scaffold provides a privileged structure that can interact effectively with these enzymatic targets.

Moreover, the carboxylate ester group in Ethyl 4-chloroquinoline-6-carboxylate offers opportunities for further derivatization into amides or other pharmacologically relevant functional groups. This flexibility has enabled the synthesis of a series of analogs with enhanced potency and selectivity. Such modifications are essential for optimizing drug candidates during preclinical and clinical development phases.

The pharmacological profile of derivatives derived from Ethyl 4-chloroquinoline-6-carboxylate has been extensively studied in vitro and in vivo. Preclinical data suggest that these compounds exhibit promising activities against various disease models, including cancer cell lines and infectious agents. The ability to fine-tune their chemical structure has allowed researchers to identify lead compounds with favorable pharmacokinetic properties. These findings underscore the importance of this intermediate in drug discovery pipelines.

In conclusion, Ethyl 4-chloroquinoline-6-carboxylate (CAS No. 148018-34-2) is a versatile and highly valuable compound in pharmaceutical synthesis. Its unique structural features and reactivity make it an indispensable tool for medicinal chemists seeking to develop novel therapeutic agents. As research continues to uncover new applications and synthetic methodologies, this compound is poised to remain at the forefront of drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)